Literature DB >> 21919556

Warfarin prophylaxis in patients after total knee or hip arthroplasty--international normalized ratio patterns and venous thromboembolism.

Beth L Nordstrom1, Sumesh Kachroo, Kathy H Fraeman, Edith A Nutescu, Jeff R Schein, Alan Fisher, Brahim K Bookhart.   

Abstract

OBJECTIVE: Warfarin is frequently used for the prevention of venous thromboembolism (VTE) after total hip or knee arthroplasty (THA/TKA). The current study was conducted to determine the association between international normalized ratio (INR) levels and VTE outcomes.
METHODS: Patients who received warfarin following THA/TKA were followed for up to 90 days using an electronic health record database. INR measurements were categorized based on American College of Chest Physicians (ACCP) guidelines. Cox proportional hazards models were used to compare the risk of VTE between patients with INR levels below and within the ACCP-recommended range in patients with ≥2 available INR level measurements.
RESULTS: On or after Day 5, 33.3% and 28.6% of INR levels fell within the ACCP-recommended range for THA and TKA, respectively. VTE was diagnosed in 3% of each cohort. INR levels varied over time and were frequently below the ACCP-recommended range. Below-range INR levels were associated with greater risk of VTE in both THA (hazard ratio [HR]: 5.29; 95% CI: 2.64-10.61) and TKA (HR: 4.64; 95% CI: 2.59-8.29).
CONCLUSIONS: In the current study, the majority of patients had INR levels below the ACCP-recommended range of 2.0-3.0 during warfarin exposure following orthopedic surgery. INR levels below 2.0 were associated with a four- to five-fold increase in the risk of VTE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21919556     DOI: 10.1185/03007995.2011.614938

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  5 in total

1.  Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial.

Authors:  Brian F Gage; Anne R Bass; Hannah Lin; Scott C Woller; Scott M Stevens; Noor Al-Hammadi; Jeffrey L Anderson; Juan Li; Tomás Rodriguez; J Philip Miller; Gwendolyn A McMillin; Robert C Pendleton; Amir K Jaffer; Cristi R King; Brandi Whipple; Rhonda Porche-Sorbet; Lynnae Napoli; Kerri Merritt; Anna M Thompson; Gina Hyun; Wesley Hollomon; Robert L Barrack; Ryan M Nunley; Gerard Moskowitz; Victor Dávila-Román; Charles S Eby
Journal:  JAMA       Date:  2019-09-03       Impact factor: 56.272

2.  Thromboembolic prophylaxis in total joint arthroplasty.

Authors:  David Knesek; Todd C Peterson; David C Markel
Journal:  Thrombosis       Date:  2012-09-16

3.  A common data model to assess cardiovascular hospitalization and mortality in atrial fibrillation patients using administrative claims and medical records.

Authors:  Mary P Panaccio; Gordon Cummins; Charles Wentworth; Stephan Lanes; Shannon L Reynolds; Matthew W Reynolds; Raymond Miao; Andrew Koren
Journal:  Clin Epidemiol       Date:  2015-01-12       Impact factor: 4.790

4.  The association of body mass index with the risk of type 2 diabetes: a case-control study nested in an electronic health records system in the United States.

Authors:  Michael L Ganz; Neil Wintfeld; Qian Li; Veronica Alas; Jakob Langer; Mette Hammer
Journal:  Diabetol Metab Syndr       Date:  2014-04-03       Impact factor: 3.320

5.  A dedicated anticoagulation clinic does not improve postoperative management of warfarin after total joint arthroplasty.

Authors:  Joshua S Bingham; Christopher G Salib; Kyle Labban; Zachary Morrison; Mark J Spangehl
Journal:  Arthroplast Today       Date:  2018-06-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.